Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patientsSTRUBLE, K; PISCITELLI, S. C.American journal of health-system pharmacy. 1999, Vol 56, Num 22, pp 2343-2348, issn 1079-2082Article

A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infectionPISCITELLI, S. C; BHAT, N; PAU, A et al.Drug safety. 2000, Vol 22, Num 1, pp 19-31, issn 0114-5916Article

New oral macrolide and fluoroquinolone antibiotics : an overview of pharmacokinetics, interactions, and safetyRODVOLD, K. A; PISCITELLI, S. C.Clinical infectious diseases. 1993, Vol 17, pp S192-S199, issn 1058-4838, SUP1Conference Paper

Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbitsGROLL, A. H; PETRAITIS, V; PETRAITIENE, R et al.Antimicrobial agents and chemotherapy. 1999, Vol 43, Num 10, pp 2463-2467, issn 0066-4804Article

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infectionDAVEY, R. T; CHAITT, D. G; DEWAR, R et al.The Journal of infectious diseases. 1999, Vol 179, Num 4, pp 849-858, issn 0022-1899Article

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits : efficacy, safety and non-compartmental pharmacokineticsGROLL, A. H; GONZALEZ, C. E; GIRI, N et al.Journal of antimicrobial chemotherapy (Print). 1999, Vol 43, Num 1, pp 95-103, issn 0305-7453Article

High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studiesGROLL, A. H; MICKIENE, D; WERNER, K et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 735, Num 1, pp 51-62, issn 1387-2273Article

Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutaminePISCITELLI, S. C; THIBAULT, A; FIGG, W. D et al.Journal of clinical pharmacology. 1995, Vol 35, Num 4, pp 368-373, issn 0091-2700Article

The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancerRUSHING, D; RABER, S. R; RODVOLD, K. A et al.Cancer. 1994, Vol 74, Num 3, pp 834-841, issn 0008-543XArticle

Therapeutic monitoring and pharmacist intervention in a Hansen's disease clinicPISCITELLI, S. C; OCCHIPINTI, D. J; DANZIGER, L. H et al.The Annals of pharmacotherapy. 1993, Vol 27, Num 12, pp 1526-1531, issn 1060-0280Article

Protease inhibitors for the treatment of human immunodeficiency virus infectionKAKUDA, T. N; STRUBLE, K. A; PISCITELLI, S. C et al.American journal of health-system pharmacy. 1998, Vol 55, Num 3, pp 233-254, issn 1079-2082Article

Fluconazole : a new triazole antifungal agentPASKO, M. T; PISCITELLI, S. C; VAN SLOOTEN, A. D et al.DICP (Cincinnati, Ohio). 1990, Vol 24, Num 9, pp 860-867, issn 1042-9611, 8 p.Article

Atovaquone suspension in HIV-infected volunteers : Pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyFALLOON, J; SARGENT, S; LANE, H. C et al.Pharmacotherapy. 1999, Vol 19, Num 9, pp 1050-1056, issn 0277-0008Article

Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infectionPISCITELLI, S. C; FORREST, A; VOGEL, S et al.Clinical pharmacology and therapeutics. 1998, Vol 64, Num 5, pp 492-498, issn 0009-9236Article

Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patientsPISCITELLI, S. C; WELLS, M. J; METCALF, J. A et al.Pharmacotherapy. 1996, Vol 16, Num 5, pp 754-759, issn 0277-0008Article

Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transductionFIGG, W. D; COLE, K. A; SAROSY, G et al.Clinical cancer research. 1995, Vol 1, Num 8, pp 797-803, issn 1078-0432Article

Effectiveness of a dapsone compliance program in leprosyPISCITELLI, S. C; DANZIGER, L. H; HILL, C et al.International journal of dermatology. 1993, Vol 32, Num 3, pp 206-209, issn 0011-9059Article

Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectivesLAU, A. H; LAM, N. P; PISCITELLI, S. C et al.Clinical pharmacokinetics. 1992, Vol 23, Num 5, pp 328-364, issn 0312-5963Article

Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokineticsJORDAN, M. K; POLIS, M. A; KELLY, G et al.Antimicrobial agents and chemotherapy. 2000, Vol 44, Num 8, pp 2170-2172, issn 0066-4804Article

A multiple drug interaction study of stavudine with agents for opportunistic infections in human immunodeficiency virus-infected patientsPISCITELLI, S. C; KELLY, G; WALKER, R. E et al.Antimicrobial agents and chemotherapy. 1999, Vol 43, Num 3, pp 647-650, issn 0066-4804Article

Phase I study of a five-day dose schedule of 4-ipomeanol in patients with non-small cell lung cancerKASTURI, V. K; DEARING, M. P; KELLEY, M. J et al.Clinical cancer research. 1998, Vol 4, Num 9, pp 2095-2102, issn 1078-0432Article

Pharmacokinetics of fentanyl during hyperthermic, isolated lung perfusionMILLIAMS, K. S; SUSLA, G; TEMECK, B. K et al.Southern medical journal (Birmingham). 1998, Vol 91, Num 3, pp 261-265, issn 0038-4348Conference Paper

Effects of cytokines on antiviral pharmacokinetics : an alternative approach to assessment of drug interactions using bioequivalence guidelinesPISCITELLI, S. C; AMANTEA, M. A; VOGEL, S et al.Antimicrobial agents and chemotherapy. 1996, Vol 40, Num 1, pp 161-165, issn 0066-4804Article

Thalidomide in diseases associated with human immunodeficiency virus infectionMINOR, J. R; PISCITELLI, S. C.American journal of health-system pharmacy. 1996, Vol 53, Num 4, pp 429-431, issn 1079-2082Article

In vitro activities of metronidazole and its hydroxy metabolite against bacteroides sppPENDLAND, S. L; PISCITELLI, S. C; SCHRECKENBERGER, P. C et al.Antimicrobial agents and chemotherapy. 1994, Vol 38, Num 9, pp 2106-2110, issn 0066-4804Article